Treatments for macular oedema following central retinal vein occlusion: systematic review


Published in:
BMJ Open

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
BMJ Open  Treatments for macular oedema following central retinal vein occlusion: systematic review

John A Ford,¹ Christine Clar,² Noemi Lois,³ Samantha Barton,⁴ Sian Thomas,² Rachel Court,² Deepson Shyangdan,² Norman Waugh²

ABSTRACT

Objectives: To review systematically the randomised controlled trial (RCT) evidence for treatment of macular oedema due to central retinal vein occlusion (CRVO).

Data sources: MEDLINE, EMBASE, CDSR, DARE, HTA, NHS EED, CENTRAL and meeting abstracts (January 2005 to March 2013).

Study eligibility criteria, participants and interventions: RCTs with at least 12 months of follow-up assessing pharmacological treatments for CRVO were included with no language restrictions.

Study appraisal and synthesis methods: 2 authors screened titles and abstracts and conducted data extracted and Cochrane risk of bias assessment. Meta-analysis was not possible due to lack of comparable studies.

Results: 8 studies (35 articles, 1714 eyes) were included, assessing aflibercept (n=2), triamcinolone (n=2), bevacizumab (n=1), pegaptanib (n=1), dexamethasone (n=1) and ranibizumab (n=1). In general, bevacizumab, ranibizumab, aflibercept and triamcinolone resulted in clinically significant increases in the proportion of participants with an improvement in visual acuity of ≥15 letters, with 40–60% gaining ≥15 letters on active drugs, compared to 12–28% with sham. Results for pegaptanib and dexamethasone were mixed. Steroids were associated with cataract formation and increased intraocular pressure. No overall increase in adverse events was found with bevacizumab, ranibizumab, aflibercept or pegaptanib compared with control. Quality of life was poorly reported. All studies had a low or unclear risk of bias.

Limitations: All studies evaluated a relatively short primary follow-up (1 year or less). Most had an unmasked extension phase. There was no head-to-head evidence. The majority of participants included had non-ischaemic CRVO.

Conclusions and implications of key findings: Bevacizumab, ranibizumab, aflibercept and triamcinolone appear to be effective in treating macular oedema secondary to CRVO. Long-term data on effectiveness and safety are needed. Head-to-head trials and research to identify ‘responders’ is needed to help clinicians make the right choices for their patients. Research aimed to improve sight in people with ischaemic CRVO is required.

INTRODUCTION

Central retinal vein occlusion (CRVO) is a vascular disorder of the retina with often catastrophic consequences to vision and quality of life.¹ ² The incidence of CRVO increases with age; most individuals affected are 50 years of age or older.³ It has been estimated that there are around 80 new cases of CRVO/million population/year.⁴ ⁵ Although CRVO most commonly affects one eye, in around 10% of patients the disease affects both eyes.² Approximately 20% of patients with CRVO will develop large areas of retinal non-perfusion (ischaemia).⁶ Furthermore, a small proportion (around 8%) of patients with non-ischaemic CRVO may convert into the ischaemic type during follow-up.⁵ Retinal ischaemia may lead to the development of neovascularisation in the retina, iris or anterior chamber angle. Complications of neovascularisation include vitreous haemorrhage and neovascular glaucoma.⁶ Currently, there is no treatment for ischaemic CRVO other than that aimed at ameliorating the severity of complications, with treatments such as panretinal photocoagulation. Even with the use of current therapies, some eyes with ischaemic CRVO end up blind and painful and, ultimately, enucleation (removal of the eye) is necessary to provide comfort to patients.

Not all people with CRVO will require treatment and macular oedema will resolve in about a third of those with non-ischaemic CRVO.² ⁷ However, most will need treatment...
and the number of options has increased in recent years. Laser photocoagulation has been, for many years, the standard therapy for patients with macular oedema secondary to branch retinal vein obstruction (BRVO).8 However, laser treatment was not found to be beneficial to those with macular oedema secondary to CRVO; for these patients, no therapeutic modalities could be offered. Recently, several studies have demonstrated the benefit of antivascular endothelial growth factor (VEGF) therapies and steroids for the management of patients with macular oedema secondary to CRVO. Steroids, such as triamcinolone and dexamethasone, have anti-inflammatory and antiproliferative attributes (as well as some anti-VEGF effects) and therefore are primarily effective by reducing the oedema of the macula. Anti-VEGF treatments, such as bevacizumab, ranibizumab, aflibercept and pegaptanib, inhibit vascular endothelial growth factor A. In CRVO there is an increase in vascular endothelial growth factor A which leads to neovascularisation and oedema. In the UK, National Institute for Health and Care Excellence (NICE) has approved dexamethasone (in the long-acting form, Ozurdex) and ranibizumab (Lucentis) and an appraisal of aflibercept is currently underway. Bevacizumab is also used, but is not licensed for use in the eye; however this is because the manufacturer has never sought a license, preferring to market ranibizumab. Triamcinolone has also been used off license.

An up-to-date review incorporating all drug treatments for macular oedema secondary to CRVO is needed. The purpose of this study is to review systematically the randomised controlled evidence for drug treatments of macular oedema secondary to CRVO.

**METHODS**

A systematic review was conducted. The following databases were searched: MEDLINE, MEDLINE In-process, EMBASE (all via OVID); CDSR, DARE, HTA, NHSEED, CENTRAL (all via The Cochrane Library); Science Citation Index and Conference Proceedings Citation Index-Science (via Web of Knowledge). In addition to the bibliographic database searching, supplementary searches were undertaken to look for recent and unpublished studies in the WHO International Clinical Trials Registry Platform and ophthalmology conference websites (American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology from 2010 to 2012).

**Search strategy**

An iterative procedure was used to develop two search strategies with input from previous systematic reviews.14 15 The first search strategy was designed to retrieve articles reporting randomised controlled trials (RCTs) or systematic reviews about CRVO published from 2005 onwards (the publication date of the first RCT on triamcinolone in MEDLINE). Terms for retinal vein occlusion were included to ensure identification of articles in which BRVO and CRVO were covered, but were reported separately. The second strategy focussed on retrieving articles where adverse events of relevant pharmacological treatments for CRVO were reported. This second search was limited by condition (age-related macular degeneration (AMD) or RVO), study type (RCTs, SRs or observational studies) and date (published from 2010 onwards). Searches were conducted in March 2013. The strategies used in each database are provided in online supplementary appendix 1. Automatic alerts of searches were set up to capture relevant articles published after the dates of the searches.

Reference lists from the included studies and identified systematic reviews were screened.

**RCTs and exclusion criteria**

RCTs were used to assess the clinical effectiveness and adverse events.

Only RCTs examining pharmacological treatment compared with laser treatment, observation, placebo (sham injection) or another pharmacological intervention with at least 12 months follow-up were included. Comparisons of different doses of drugs were not included unless there was an additional comparator group as defined above. Studies including CRVO and BRVO were included provided participants with CRVO were reported as a subgroup. Studies assessing treatments aimed at restoring circulation to the occluded vein shortly after onset (<30 days) were excluded. There were no language restrictions.

**Outcomes**

The primary outcome was visual acuity measured as mean change in best-corrected visual acuity (BCVA) or as proportion of patients improving by 15 Early Treatment for Diabetic Retinopathy Study (ETDRS) letters or more. Secondary outcomes included mean change in macular thickness using optical coherence tomography (OCT), quality of life and adverse events.

**Screening and data extraction**

Search results were screened independently by two authors (CC, JAF and ST). Differences were resolved through discussion or by consulting a third author (JAF). Data were extracted by one author (CC and DS) and checked by a second (ST, CC). Data extraction included inclusion/exclusion criteria, baseline demographics, mean change in BCVA, proportion of patients with 15 letters improvement, central retinal thickness (CRT) and adverse events. Risk of bias was assessed by two reviewers using the Cochrane risk of bias tool.16 Meta-analysis was not possible because of a lack of comparable studies.
RESULTS

Search results

The study flow is shown in figure 1. The electronic searches yielded 518 records. A total of 475 were eliminated based on information in the titles and abstracts. The full text of the remaining 43 records was checked, and a further eight were eliminated. Reasons for exclusion included the trial being a commentary rather than an RCT, the study having no relevant comparison group (dose ranging only), the participants did not have macular oedema secondary to CRVO, or the interventions being ineligible (non-pharmacological). The remaining 35 records (including conference abstracts) reported on eight RCTs of six different pharmacological agents, and these were included in the analysis. The Geneva study (2010)\textsuperscript{11} 17 18 technically consists of two RCTs, but as these were analysed and reported together, it was counted as one RCT in this analysis.

We also identified three relevant ongoing trials, one investigating minocycline (http://clinicaltrials.gov/ct2/show/study/NCT01468844), one investigating a combination of bevacizumab and triamcinolone (http://clinicaltrials.gov/show/NCT00566761) and one investigating ranibizumab (http://clinicaltrials.gov/show/NCT01123564).

Study characteristics

Detailed study characteristics of the included studies are shown in online supplementary table S1.

Study design

Of the eight included RCTs, six were described as double-blinded and seven were sham-controlled. All but one were multicentre. Only one was not funded by industry. Four trials were international trials, two came from the USA, and one each from Austria and Sweden. Six of the trials measured primary endpoints at around 6 months (24–30 weeks), whereas two measured primary endpoints at 12 months. Five studies reported follow-up data for up to 12 months, and two reported data for follow-up periods of up to 2 years.

Participants

The trials randomised a total of 1714 eyes (1 eye/person). The number of eyes per study ranged between 60 and 437. Follow-up at the primary endpoint ranged from 77% to 98% (generally over 90% in the intervention groups). The participants had a mean age of between 59 and 70.5 years, and between 36% and 49% were female. Only two studies reported mean duration of macular oedema (4.3 and 4.9 months). Five studies reported mean time since CRVO diagnosis (range 2.4–2.9 months). Mean baseline BCVA was between 44 and 52.5 ETDRS letters, baseline CRT was between 569 and 721 µm. In most trials, the focus was on macular oedema secondary to CRVO only, but in the Geneva trial macular oedema secondary to BRVO and CRVO was included and only limited data were available on the CRVO-only group.

Interventions

The Geneva trial (2010 ff.)\textsuperscript{11} 17 18 compared a 0.35 mg (n=136) and a 0.7 mg dexamethasone (n=154) intravitreal implant with sham treatment (n=147). After the initial 6-month study period, patients could enter a 6-month open label extension, where they received a 0.7 mg dexamethasone intravitreal implant.

The Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) trial (2009 ff.)\textsuperscript{19–32} compared intravitreal injections of 1 or 4 mg of triamcinolone (~2 injections over 12 months, n=92 and 91 for 1 and 4 mg, respectively) with an observation group (n=88). Two forms of triamcinolone have been used in trial; the SCORE trial used Trivaris, rather than Kenalog. Trivaris is no longer available because its manufacturer has promoted an alternative steroid (dexamethasone). The Radial Optic Neurotomy for Central Vein Occlusion (ROVO) trial (2013)\textsuperscript{33} compared a single intravitreal injection of 4 mg of triamcinolone (over 12 months, n=25) with radial optic neurotomy (n=38) or sham injection (n=20).

In the Carvedilol Prospective Randomised Cumulative Survival (COPERNICUS) trial (2012)\textsuperscript{34} 35 intravitreal injections of 2 mg of aflibercept (n=114) were given every 4 weeks for over 24 weeks to the intervention group and the comparison group received a sham injection (n=75). During weeks 24–52, patients in both groups received aflibercept if they met protocol-specified retreatment criteria and received a sham injection if retreatment was not indicated (3.9 SE 0.3 injections in the sham group and 2.7 SE 0.2 injections in the aflibercept group); after the first year, patients continued in an 1-year extension phase with as needed dosing. In the GALILEO trial (2012)\textsuperscript{36} 37 intervention patients also received intravitreal injections of 2 mg of aflibercept (n=103) every 4 over 24 weeks, while the comparison group was given sham injections (n=71). During weeks 24–52, patients remained in their original treatment groups but received their allocated treatment as needed; beginning from weeks 52 to 76, both groups received the study drug every 8 weeks.

In a trial by Wroblewski and colleagues,\textsuperscript{38–44} patients received 0.3 or 1 mg intravitreal injections of pegaptanib sodium every 6 for 24 weeks (n=33 and 33), compared with a sham injection group (n=32). Patients were followed up to 52 weeks.

The Central Retinal Vein Occlusion (CRUISE) trial (2010 ff.)\textsuperscript{10} 45 46 compared monthly injections of 0.3 or 0.5 mg of ranibizumab (n=132 and 130) over 6 months with sham injection (n=130). During months 6–12, all patients could receive intracocular ranibizumab (previously assigned dose or 0.5 mg for the sham group) if they met prespecified functional and anatomic criteria; after 12 months’ follow-up patients could continue in the Health Outcomes and Reduced Incidence with
Zoledronic Acid Once Yearly (HORIZON) trial for another 12 months, where they were eligible to receive intravitreal injections of 0.5 mg ranibizumab if they fulfilled prespecified criteria.

Epstein et al.47–49 conducted an RCT in which they compared patients receiving four intravitreal injections of 1.25 mg of bevacizumab (n=30) over 6 months with patients receiving sham injections (n=30). From 6 to 12 months, all patients received intravitreal bevacizumab injections every 6 weeks.

Outcomes
The primary endpoint of all but one study was the proportion with a gain of 15 or more ETDRS letters. The primary endpoint of the remaining study was mean change in BCVA. Studies also reported gains or losses of ETDRS letters at various cut-off points, absolute BCVA, CRT and safety parameters. The COPERNICUS, the GALILEO and the CRUISE studies also measured vision-related quality of life (National Eye Institute Visual Functioning Questionnaire, NEI-VFQ).10 34–37 45 46 EQ5D was also used in GALILEO.

Ongoing studies
Ongoing trials are shown in online supplementary table S4, the first (clinicaltrials.gov NCT01468844) is a 24-month double-blind RCT from the USA. It set out to test the safety and effectiveness of minocycline as a treatment for CRVO in around 20 patients with macular oedema secondary to CRVO. Both groups received monthly intravitreal bevacizumab injections over 3 months (and afterwards as needed), and the intervention group also received 100 mg oral minocycline twice daily over 24 months. The second trial (clinicaltrials.gov NCT00566761) is an open-label RCT from Mexico in only around 10 patients assessing whether combined treatment with bevacizumab and triamcinolone is more effective than bevacizumab alone. The combination group received 2.5 mg of bevacizumab plus 4 mg of triamcinolone as a first dose and then two doses of bevacizumab alone at monthly intervals, while the monotherapy group received three monthly doses of 2.5 mg bevacizumab alone. Follow-up will be 12 months. A third RCT from Hungary compares monthly injections of ranibizumab for 3 months (and as needed thereafter) with Argon laser treatment in around 40 patients with macular oedema secondary to CRVO. Follow-up will also be 12 months. The primary endpoint in all studies is BCVA over 12 months.
the allocation sequence, but only half the studies gave enough details to confirm adequate allocation concealment. Most studies (unclear in the ROVO 2013 study) used at least partial masking, and most studies appeared to have had masking of outcome assessment. Intention-to-treat analysis was used in all studies. Where reported separately for comparison groups, losses to follow-up tended to be slightly higher for the control groups than the interventions groups (79–88.5% follow-up in the control groups and 90–98% in the intervention groups). All studies appeared to have been free of selective reporting. Most studies included a power analysis (not reported for the CRUISE study) but in two cases (the SCORE and the ROVO studies) the numbers randomised were considerably below the numbers indicated in the power calculations. As far as reported, there were no significant differences between comparison groups in baseline characteristics.

**Clinical effectiveness**

Detailed study results can be found in online supplementary table S2.

**Visual acuity**

Figure 2 shows the primary endpoint in most studies, which was the proportion of participants with a gain of 15 or more ETDRS letters. As there were no significant differences in visual acuity results between groups using different dosages of the given pharmacological treatment, intervention groups were combined for the sake of the plot.

In the Geneva trial (2010 ff.), treatment of macular oedema secondary to CRVO with a 0.7 mg intravitreal dexamethasone implant resulted in a 0.1 letter gain in BCVA compared to a loss of 1.8 in the sham group (p<0.001). The difference persisted in the extension period where all patients received the 0.7 mg dexamethasone implant. However, there was no significant difference in the proportion of patients gaining or losing 15 letters at either 6 or 12 months (0.35 or 0.7 mg dexamethasone). This may reflect the timing of peak effect at 90 days with dexamethasone.

In the SCORE trial (2009 ff.), patients in the triamcinolone groups lost significantly fewer ETDRS letters (triamcinolone 1 mg 1.2 letters loss, 4 mg 1.2 letters loss and observation 12.1 letters loss) over both 12 and 24 months than patients in the observation group. The proportion of patients gaining 15 letters or more was also significantly larger in the intervention groups at 12 and 24 months (25.6% compared with 6.8% and 31% compared with 9%, respectively). The proportion of patients receiving triamcinolone and losing 15 letters or more was smaller (25.6%) than in the observation group (43.8%), but this difference was not statistically significant (p=0.06).

There was some overall improvement in BCVA in both intervention groups at 12 months in the ROVO trial (2013; triamcinolone 20%, radial optic neurotomy 47% and sham 10%); however, it was unclear whether there were any statistically significant differences between the 4 mg triamcinolone, the radial optic neurotomy or the sham group. However, there were significantly more patients with an improvement of more than or equal to 15 letters in the neurotomy group than in the sham group (47% vs 10%), but no significant difference to sham after one dose of triamcinolone.

In the COPERNICUS (2012) and GALILEO (2012) trials, patients in the aflibercept group had a significant improvement in BCVA at 6 months of 18 and 17.3 letters (compared with 4 letters loss and 3.3 letter gain in sham groups, respectively) and this was maintained at 12 months and was significantly greater than the improvements in the sham groups. This was paralleled by a significantly greater proportion of patients

---

**Figure 2** Study results for the primary outcome (≥15 Early Treatment for Diabetic Retinopathy Study letter gain).
pared with sham.

implant (no data given for the 0.35 mg implant) com-
to CRVO with the 0.7 mg intravitreal dexamethasone
of treatment in patients with macular oedema secondary
cence was found in the reduction of CRT after 6 months
Central retinal thickness
tended to have better visual outcomes than older
receiving bevacizumab. Younger patients (<70 years)

(2013)33 but there was no signi-
decreased in all comparison groups in the ROVO trial
there was no clear difference in the proportion of
all study groups, but there was no significant difference
in the SCORE trial (2009 ff.),19–32 CRT decreased in
all groups. There was no significant difference
in the COPERNICUS trial (2012)34 35 and in the
GALILEO trial (2012)36 37 there was a significantly
greater reduction in CRT at 6 months in the aflibercept
group than in the control group. However, the
significant difference was maintained in the longer term
only in the GALILEO trial, where patients continued
their assigned treatment up to 12 months. In the
COPERNICUS trial, patients in the sham group also
received aflibercept in the extension period, which
caus ed a similar decrease in CRT as in the original inter-
vention group.

After 30 weeks of treatment with pegaptanib
(Wroblewski and colleagues),38–44 differences in
decrease of CRT versus sham did not reach significance,
but at 52 weeks, the decrease in CRT was significantly
greater in both the 0.3 mg and the 1 mg pegaptanib
groups compared with sham.

After treatment with ranibizumab in the CRUISE trial
(2010 ff.)10 45 46 a significant reduction in CRT was
observed and significantly more patients achieved a CRT
of 250 µm or less in the intervention groups (no differ-
cence between doses) than in the sham group at
6 months. This difference did not persist at 12 and
24 months because all groups received ranibizumab as
needed.

In the CRUISE trial, patients in the sham group who received bevacizumab in the
extension period, similar decreases in CRT and increases in
the proportion of patients with no residual oedema were
seen.

Vision-related quality of life
Vision-related quality of life (NEI-VFQ25) was signi-
ficantly higher in the aflibercept group, compared with
sham injection, at 6 months in the COPERNICUS trial
(+7.2 compared with +0.8)34 35 and the GALILEO trial
(+7.5 compared with +3.5).36 37 In the COPERNICUS
trial, patients in the sham group who received afliber-
cept in the extension period had a similar increase in
vision-related quality of life as patients in the original
intervention group by 12 months.

In the CRUISE trial (2010 ff.)10 45 46 vision-related
quality of life (NEI-VFQ) was similarly increased in both
ranibizumab groups and statistically significantly more
than in the sham group at 6 months (+6.2 compared
with +2.8). At 12 months, with all groups receiving rani-
bizumab as needed, the increases were similar in all
three groups.

Adverse events
The 0.7 mg dexamethasone intravitreal implant caused
significantly more increased intraocular pressure (IOP)
than sham treatment (30.1% vs 1.4% in the control
group) in patients with CRVO in the Geneva trial (2010
ff.,11 17 18; not reported for 0.35 mg). The incidence of
cataract was also slightly higher in the dexamethasone
group but numbers were small because of the short
duration. There were no other differences in adverse events
between groups.

Central retinal thickness
In the Geneva trial (2010 ff.),11 17 18 no significant differ-
ence was found in the reduction of CRT after 6 months
of treatment in patients with macular oedema secondary
to CRVO with the 0.7 mg intravitreal dexamethasone
implant (no data given for the 0.35 mg implant) com-
pared with sham.

In the SCORE trial (2009 ff.),19–32 CRT decreased in
all groups. There was no significant difference
between groups at either 12 or 24 months. Similarly,
there was no clear difference in the proportion of
patients achieving a CRT of less than 250 µm. CRT
decreased in all comparison groups in the ROVO trial
(2013).35 but there was no significant difference between
groups.

In the COPERNICUS trial (2012)34 35 and in the
GALILEO trial (2012)36 37 there was a significantly
greater reduction in CRT at 6 months in the aflibercept
group than in the control group. However, the
In the triamcinolone group (especially 4 mg, SCORE trial 2009 ff.), there was a higher increase in IOP, lens opacity onset or progression (at 12 months) and cataract surgery (12–24 months) than in the control group. There were no other differences in adverse events between groups. A similar tendency was seen in the ROVO trial (2013).33

Afibercept did not appear to increase the incidence of ocular or non-ocular adverse events compared with sham in both the COPERNICUS trial (2012) and the GALILEO trial (2012).36 37

In the trial by Wroblewski and colleagues,38–44 adverse events in response to pegaptanib were not reported in detail, but there do not appear to have been any serious ocular or systemic adverse events.

After treatment with ranibizumab in the CRUISE trial (2010 ff.),40 45 46 there were no consistent differences in ocular or systemic adverse events between the intervention groups. None of the ocular adverse events appeared to have increased substantially after all patients received ranibizumab up to 24 months.

Epstein et al47–49 did not report adverse events in response to bevacizumab in detail, but the treatment appears not to have caused any serious ocular adverse events over 48 weeks.

DISCUSSION

Statement of principal findings

Evidence from good quality RCTs shows that intravitreal steroids and anti-VEGF therapies increase the proportion of patients whose vision improves by 15 or more letters in patients with macular oedema secondary to CRVO. The most effective drugs result in over 60% of patients gaining 15 letters compared with only about 20% of the control groups. The RCT evidence shows only short-term effectiveness of ranibizumab, bevacizumab, afibercept and triamcinolone. Results from trials of dexamethasone and pegaptanib were mixed. Long-term evidence is awaited.

Strengths and limitations

A robust systematic review methodology was used. A broad search strategy was implemented, which included not restricting the search strategy with drug terms. Grey literature was searched by screening meeting abstracts from relevant conferences. There were no language restrictions. Two reviewers screened titles and abstracts and conducted data extraction and risk of bias assessment. Risk of bias was assessed using the Cochrane Risk of Bias Tool and was generally judged to be low or unclear. Only studies with 1-year follow-up were included to exclude studies with very short follow-up RCTs were identified for all the new ophthalmological drugs, except for the steroid, fluocinolone.

The main limitation is the short duration of follow-up. The primary outcome for most trials was measured at 6 months, with an extension phase of up to 12 months. Hence, it is not known whether the benefit of these treatments will be maintained long term. Furthermore, potential side effects of these treatments may not be captured in these studies as a result of their short follow-up. Patients and clinicians would like sustained, life-long improvement in visual acuity, but of all included studies only one of them had a follow-up of over 24 months.

The sample size of some studies was small. For example, the evidence for pegaptanib and bevacizumab comes from studies with around 30 participants/arm which substantially increases the risk of a type II error. Only three trials included quality of life data, arguably one of the most important outcomes.

The proportion of participants and severity of ischaemia within the trials was not clear. While ischaemia is not mentioned in the inclusion/exclusion criteria of most studies, these participants were unlikely included in these studies, especially if the diagnosis of ischaemic CRVO is based on strict criteria. Furthermore, patients were entered into the trials relatively soon after diagnosis (mean 4.3–4.9 months) and it is not clear if the effects would be similar in patients who present with long-standing disease.

Another limitation was that patients were not asked at the trials, what treatment they thought they had received, which would have provided data on the success of masking of allocation.

In the case of dexamethasone, the results at 6 months were not as good as at 90 days, because of the duration of action. Earlier retreatment, at say 120 days, would have improved results, but many clinicians might be reluctant to repeat injections of dexamethasone implant often because of the large needle size and risk of adverse effects.

Adverse events

Results from the included studies clearly demonstrate that steroids (triamcinolone and dexamethasone) are associated with clinically meaningful increases in IOP and cataract progression. Anti-VEGF therapy ocular adverse events reported in the trials were similar in both placebo and intervention arms.

There is limited evidence of the safety of these drugs specifically in CRVO, but it would not be unreasonable to look to trials in neovascular AMD and diabetic macular oedema (DMO) for safety data, where there is more experience. The comparison of AMD treatment trial, which compared bevacizumab with ranibizumab in AMD, suggested that there was a higher incidence (relative risk (RR) 1.29; 95% CI 1.01 to 1.66) of serious systematic adverse events (primarily hospitalisations) in the bevacizumab arm.50 Some have raised concerns about arterial thromboembolic events with bevacizumab, but none of these has been demonstrated in the published literature.51–54 Micieli et al55 undertook a systematic review of the adverse events associated with bevacizumab. Twenty-two studies were reviewed, representing 12 699 participants.56 Adverse events in patients treated...
with bevacizumab were cerebrovascular events (0.21%), myocardial infarction (0.19%) and increased blood pressure (0.46%). Most of these represent the background burden of disease in patients with advanced eye disease. The proportion of these directly attributable to bevacizumab is likely to be very small. Campbell et al undertook a nested case-control study of over 7000 cases and 37,000 controls. Ranibizumab and bevacizumab injection was the exposure and cardiovascular events were the outcome. The authors found that ranibizumab and bevacizumab were not associated with increased cardiovascular events.

Increased IOP has been associated with ranibizumab, bevacizumab and pegaptanib. Sustained increased in IOP has estimated to be 5.5–6% with these drugs. Robust evidence on the long-term safety of aflibercept is awaited.

**What do these results mean?**

Until very recently, patients with macular oedema as a result of CRVO could only be offered visual rehabilitation and visual aids in an attempt to help them to deal better with their reduced vision and its implications in their daily activities and quality of life. Their future is brighter now as new options to treat macular oedema have become available. Tramcinolone is likely to be a cost-effective treatment at least in selected groups of patients, such as pseudophakic individuals or those with pre-existing cataracts that may require cataract surgery in the near future. The lack of a commercially available licensed product for intraocular administration may restrict its use in clinical practice.

Some anti-VEGF therapies, including bevacizumab, ranibizumab and aflibercept, have also been shown to be effective in short-term studies for the treatment of patients with macular oedema and CRVO. Bevacizumab has the advantage of having a low cost, with an apparently similar effect to other anti-VEGF therapies but there is some reluctance to use it as it is not licensed for use in the eye. This has been seen in other eye conditions, such as AMD and DMO. Aflibercept, requiring potentially fewer injections than other anti-VEGF agents, could represent an advantage to patients and may relieve pressure on ophthalmology clinics. Healthcare systems will need to evaluate the cost-effectiveness of these new treatments and support affordable ones. The NICE is currently appraising aflibercept. Policy makers are left in a difficult position because of bevacizumab. It is cheaper than all other drugs and appears to be as effective, but is unlicensed and unlike ranibizumab and aflibercept does not have evidence from large, well-funded RCTs in CRVO. The use of bevacizumab would result in considerable savings for the NHS.

It is important to note that the evidence of benefit of these new therapies is likely to only apply to patients with non-ischaemic CRVO. Although some patients with ischaemic CRVO were included, these individuals are likely to have mild ischaemic CRVO. Thus, for patients with established ischaemic CRVO, there are no proven treatments available and further research into this area is very much needed.

**What is the context of these results**

Earlier systematic reviews identified limited evidence on the clinical effectiveness of treatments. A review by Braithwaite et al (search date August 2010) on anti-VEGF agents identified one RCT comparing two doses of ranibizumab and one RCT comparing two doses of pegaptanib sodium versus placebo or no treatment. In both RCTs, the higher dose of the anti-VEGF significantly improved BCVA compared with sham injection in the short term (~6 months), but the effects in the longer term were unclear. Braithwaite and colleagues concluded that data from the two RCTs could not be synthesised because ranibizumab and pegaptanib sodium might not be directly comparable. Subsequent RCTs identified in this review also suggest benefit in ocular outcomes in macular oedema secondary to non-ischaemic CRVO for the anti-VEGFs bevacizumab and aflibercept.

Gewaily and Greenberg reviewed the literature on intravitreal corticosteroids (search date November 2008) versus observation in macular oedema secondary to CRVO and identified no relevant RCTs. Results from two observational studies suggested that triamcinolone acetonide might be beneficial in the treatment of macular oedema secondary to non-ischaemic CRVO. However, as the authors of the review caution because conclusions are primarily drawn from small case series and case reports with short follow-up. Results from the SCORE 2009 RCT corroborate the observational studies. The effects of triamcinolone acetonide in people with non-ischaemic CRVO without associated macular oedema are less clear. Data from four observational studies led Gewaily and Greenberg to conclude that intravitreal corticosteroids are associated with transient anatomical and functional improvements.

Immediate treatment aimed at relieving the blocked vein and surgical interventions were out with the remit of this review. Antithrombotics, such as low-molecular weight heparin (LMWH), and fibrinolytics have also been found to benefit visual acuity in retinal vein occlusion with no associated macular oedema. Two systematic reviews identifying the same three RCTs in recent onset (<30 days) BRVO or CRVO found that LMWH improved visual acuity compared with aspirin and that the associated benefit was larger in CRVO; only one of the three RCTs included people solely with CRVO. One review also included one RCT comparing ticlopidine with placebo and two RCTs assessing intravenous fibrinolytic therapy followed by warfarin or aspirin with either haemodilution or no treatment. The authors of the reviews conclude that no definitive recommendations can be made on clinical effectiveness of LMWH in CRVO given the limited evidence available.

Radial optic neurotomy involves the performance of a radial cut using a microvitreoretinal blade through the
lamina cribrosa, scleral ring and adjacent sclera at a selected point in the optic nerve head with the goal of ‘decompressing’ the scleral outlet (space confined by the scleral ring and containing the lamina cribrosa, the central retinal artery, central retinal vein and the optic nerve). The ROVO trial found radial optic neurotomy to be more effective than sham.

While this review was being considered for publication, another was published, with differences in scope (BRVO and CRVO) and inclusions (this review is more up-to-date). The reviewers found that aflibercept and bevacizumab resulted in greatest gain, followed by ranibizumab and triamcinolone. The overall conclusions in both reviews were similar.

Further research
Large adequately powered RCTs comparing ranibizumab, bevacizumab, aflibercept and triamcinolone are needed. Part of the problem is that the US Food and Drug Administration requires pharmaceutical companies needed. Part of the problem is that the US Food and Drug Administration requires pharmaceutical companies to present data establishing a drug’s safety and effectiveness. While this does not specifically require a placebo-controlled trial, it is the most efficient study design for demonstrating effectiveness and safety. Clinicians and researchers are left with placebo-controlled trials demonstrating effectiveness for individual drugs, but a lack of evidence to help them decide which is best for their patients.

Given the cost of these treatments and the burden of repeated injections to patients and healthcare systems, research aiming to predict ‘responders’ would be useful as at present this is performed by therapeutic trials. Treatments could then be targeted to patients likely to benefit. Research is also needed on the frequency and sequences of drugs. As other pathogenic pathways besides inflammation and VEGF-mediated pathways may be implicated in the development of macular oedema in patients with CRVO, these should be investigated in an attempt to develop new therapeutic strategies for this condition. Research is also needed into optimum timing of treatment after CRVO. The cost-effectiveness of diagnostic technologies for determining when retreatment is necessary should be examined.

We also need better treatments since a significant proportion of patients do not improve with all of these drugs. Future RCTs should include longer term outcomes, as functional results observed at 6 months or even 1 year may not necessarily be representative of what is likely to be achieved longer term and, furthermore, potential side effects of treatments, such as retinal atrophy after repeated injections of anti-VEGFs, may not be captured in short-term studies.

CONCLUSIONS
Bevacizumab, ranibizumab, aflibercept and triamcinolone appear to be effective in improving the number of patients who gain 15 letters or more in CRVO. There are mixed results for dexamethasone and pegaptanib. Steroids were associated with cataract progression and increased IOP. Long-term data on effectiveness and safety are needed. Head-to-head trials and research to identify ‘responders’ is needed to help clinicians make the right choices for their patients.

Author affiliations
1Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK
2Warwick Evidence, University of Warwick, Coventry, UK
3Centre for Vision and Vascular Science, Queen’s University, Belfast, UK
4BMJ Technology Assessment Group, London, UK
5Division of Health Sciences, Medical School, University of Warwick, Coventry, UK

Contributors NW devised the idea for the review. JAF wrote the protocol and all authors contributed to the design of the protocol. RC undertook the literature searches. JAF, CC and ST screened titles and abstracts. CC, ST and DS extracted the data. All authors contributed to the interpretation of the results. JAF, NL, RC, CC and SB contributed to the first draft of the article. All authors reviewed and commented on the final manuscript.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES


